Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept

Due to its abundant chondrogenic matrix and hypoxic tissue, chondrosarcoma is chemo- and radio-resistant. Our group has developed a proteoglycan targeting strategy by using a quaternary ammonium (QA) function as a carrier of DNA alkylating agents to chondrosarcoma environment. Here, we assessed the...

Descripción completa

Detalles Bibliográficos
Autores principales: Voissiere, Aurélien, Weber, Valérie, Gerard, Yvain, Rédini, Françoise, Raes, Florian, Chezal, Jean-Michel, Degoul, Françoise, Peyrode, Caroline, Miot-Noirault, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707064/
https://www.ncbi.nlm.nih.gov/pubmed/29221170
http://dx.doi.org/10.18632/oncotarget.21337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707064/
https://www.ncbi.nlm.nih.gov/pubmed/29221170
http://dx.doi.org/10.18632/oncotarget.21337

Ejemplares similares